The purpose of this study is to examine the effect of a pharmaceutical care program on the level of glycated hemoglobin for hyperglycemic users of brazilian public health care system in drug treatment for type 2 diabetes.
The chronic diseases, including diabetes mellitus (DM) are a major public health problems of today. There is evidence that glycated hemoglobin (A1C) levels above 7% are associated with a progressively greater risk of chronic complications related to DM. However, approximately 60% of diabetics do not achieve glycemic control. In Brazil, pharmacists are not involved in direct care of patients with DM. The investigators conducted a randomized controlled trial, for six months, in Ouro Preto, Minas terais to determine the effect of pharmaceutical intervention on glycemic control in patients with diabetes and hyperglycemic (A1C \> 7%). One hundred and twenty-nine subjects were randomized to receive usual care only or usual care and pharmaceutical intervention. The population of those who had access in the brazilian public health care system, as consultations with doctors, nurses and nutritionists, laboratory tests and access to essential medicines were considered as conventional health care.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
100
The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.
Usual care as defined in health consultations with doctors, nutritionists and nurses, access to laboratory tests and essential medicines
Universidade Federal de Ouro Preto
Ouro Preto, Minas Gerais, Brazil
GLYCATED HEMOGLOBIN (A1C) LEVELS
glycated hemoglobin levels was determined in the laboratory by high-performance liquid chromatography (HPLC) using venous blood as a sample
Time frame: AT THE BEGINNING AND END OF STUDY (AFTER 6 MONTHS OF THE START)
FASTING GLUCOSE LEVELS
fasting glucose levels was determined in the laboratory by enzymatic colorimetric method using venous blood as a sample
Time frame: AT THE BEGINNING AND END OF STUDY (AFTER 6 MONTHS OF THE START)
TOTAL CHOLESTEROL LEVELS
total cholesterol levels was determined in the laboratory by enzymatic colorimetric method using venous blood as a sample
Time frame: AT THE BEGINNING AND END OF STUDY (AFTER 6 MONTHS OF THE START)
LDL CHOLESTEROL LEVELS
LDL levels was determined in the laboratory by enzymatic colorimetric method using venous blood as a sample
Time frame: AT THE BEGINNING AND END OF STUDY (AFTER 6 MONTHS OF THE START)
HDL CHOLESTEROL LEVELS
HDL levels was determined in the laboratory by enzymatic colorimetric method using venous blood as a sample
Time frame: AT THE BEGINNING AND END OF STUDY (AFTER 6 MONTHS OF THE START)
TRIGLYCERIDES LEVELS
triglycerides levels was determined in the laboratory by enzymatic colorimetric method using venous blood as a sample
Time frame: AT THE BEGINNING AND END OF STUDY (AFTER 6 MONTHS OF THE START)
SYSTOLIC BLOOD PRESSURE LEVELS
blood pressure levels was determined by indirect method with digital sphygmomanometer, Omron HEM 742
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: AT THE BEGINNING AND END OF STUDY (AFTER 6 MONTHS OF THE START)
DIASTOLIC BLOOD PRESSURE LEVELS
blood pressure levels was determined by indirect method with digital sphygmomanometer, Omron HEM 742
Time frame: AT THE BEGINNING AND END OF STUDY (AFTER 6 MONTHS OF THE START)